Clinical Trial Update: Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the lung exposure bioequivalence of budesonide/glycopyrronium/formoterol delivered by a next-generation propellant metered-dose inhaler…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Budesonide/glycopyrronium/formoterol MDI (BGF) (budesonide/glycopyrronium/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 1 | Status: COMPLETED | Results posted: 2025-05-28